C.J. van Groeningen

Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

Cora N. Sternberg, P.H.M. de Mulder, Jan H. Schornagel et al. · Journal of Clinical Oncology · 2001 · 628 citations

Medicine, Oncology, Pharmacology +13

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

Cora N. Sternberg, PHM de Mulder, Jan H. Schornagel et al. · European Journal of Cancer · 2005 · 545 citations

Medicine, Oncology, Urology +9

Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy

Martin J. van den Bent, J. Kros, J.J. Heimans et al. · Neurology · 1998 · 203 citations

Medicine, Oncology, Pharmacology +16

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

Sophie D. Fosså, Stuart Kaye, Graham M. Mead et al. · Journal of Clinical Oncology · 1998 · 146 citations

Medicine, Oncology, Pharmacotherapy +17

Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.

C.J. van Groeningen, A. Leyva, A.M.P. O'Brien et al. · PubMed · 1986 · 121 citations · Full text

Medicine, Oncology, Pharmacology +15